Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Unrelated Umbilical Cord Blood Can Improve the Prognosis of Haploidentical Hematopoietic Stem Cell Transplantation

[Stem Cell Research & Therapy] Researchers showed that neither acute graft versus host disease (aGVHD) nor chronic GVHD was increased in the umbilical cord blood-haplo hematopoietic stem cell transplantation group, and the engraftment and infection rates were similar between the two groups.

Distinct Cellular Dynamics Associated with Response to CAR-T Therapy for Refractory B Cell Lymphoma

[Nature Medicine] Researchers performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with CD19 CAR-T products.

Chimeric Antigen Receptor T Cell Therapy for Relapsed and Refractory Thyroid Cancer

[Experimental Hematology & Oncology] Scientists showed a relapsed and refractory thyroid cancer patient treated with thyroid-stimulating hormone receptor + (TSHR) CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19.

Genetically Modified CD7-Targeting Allogeneic CAR T Cell Therapy with Enhanced Efficacy for Relapsed/Refractory CD7-Positive Hematological Malignancies: A Phase I Clinical Study

[Cell Research] Scientists developed healthy donor-derived, CD7-targeting CAR-T cells with genetic modifications to resist fratricide, graft-versus-host disease and allogeneic rejection, as well as to potentiate antitumor function.

Single-Cell Spatiotemporal Analysis Reveals Cell Fates and Functions of Transplanted Mesenchymal Stromal Cells during Bone Repair

[Stem Cell Reports] The authors developed a single-cell 3D spatial correlation (sc3DSC) method to track transplanted MSCs based on deep tissue microscopy of fluorescent nanoparticles (fNPs) and immunofluorescence of key proteins.

Allogeneic Hematopoietic Cell Transplantation Can Overcome the Adverse Prognosis Indicated by Secondary-Type Mutations in De Novo Acute Myeloid Leukemia

[Bone Marrow Transplantation] In 394 patients diagnosed with de novo acute myeloid leukemia who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed 59 patients carrying secondary-type mutations.

CBFA2T3-GLIS2 Model of Pediatric Acute Megakaryoblastic Leukemia Identifies FOLR1 as a CAR T Cell Target

[Journal of Clinical Investigation] Researchers developed CAR T cells directed against one of the targets, FOLR1, and demonstrated their pre-clinical efficacy against CBFA2T3-GLIS2 acute megakaryoblastic leukemia using in vitro and xenograft models.

Tanshinone IIA-Loaded Nanoparticle and Neural Stem Cell Therapy Enhances Recovery in a Pig Ischemic Stroke Mode

[Stem Cells Translational Medicine] Researchers evaluated the potential of Tan IIA drug-loaded nanoparticles to improve iPSC-derived neural stem cells engraftment and efficacy, thus potentially leading to enhanced cellular, tissue, and functional recovery in a translational pig ischemic stroke model.

Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response versus Non-Response

[Signal Transduction and Targeted Therapy] The authors describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.

Towards Precision Oncology with Patient-Derived Xenografts

[Nature Reviews Clinical Oncology] Investigators discuss examples from the past decade of the use of patient-derived xenograft models for precision oncology, from translational research to drug discovery.

Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

[Neurona Therapeutics] Neurona Therapeutics announced the presentation of a clinical case study from the initial dose cohort of the Phase I/II first-in-human epilepsy clinical trial of its lead program, NRTX-1001.

Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors

[Artiva Biotherapeutics, Inc.] Artiva Biotherapeutics, Inc. announced that the US FDA has cleared the company’s investigational new drug (IND) application for AB-201. AB-201 is an allogeneic HER2-targeted CAR NK cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

spot_img